痛风治疗新药——选择性尿酸重吸收抑制剂lesinurad

A new drug for gout——lesinurad, a selective uric acid reabsorption inhibitor

痛风治疗药物又添新成员。lesinurad新近分别被美国和欧盟药政当局批准上市,用于治疗痛风相关的高尿酸血症。lesinurad是迄今第一个被批准上市的选择性尿酸重吸收抑制剂。长期、持续的血尿酸水平达标治疗是治愈痛风的关键。但是,很多患者使用1种降血尿酸药物并不能使自己的血尿酸水平降至目标值以下或长期控制于目标值以下。在这种情况下,就需联合用药治疗。lesinurad正适用于这些患者,与黄嘌呤氧化酶抑制剂合用可同时达到增加尿酸排泄和减少尿酸生成的作用。

The US Food and Drug Administration and European Commission have recently approved lesinurad to treat gout-associated hyperuricemia in combination with a xanthine oxidase inhibitor （XOI）. Lesinurad is the first selective uric acid reabsorption inhibitor. The long-term management of gout entails controlling hyperuricemia, which addresses the underlying pathology of the disease. Large amount of gout patients on urate-lowering therapy remain inadequate control of uric acid. For patients who can not reach the target on an XOI alone, adding an agent that can increase uric acid excretion is recommended. Lesinurad in combination with an XOI may help those reach the normal range and improve symptoms long-term.